SEC Form 4 · accession 0001144204-18-050737
Marker Therapeutics, Inc. · MRKR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Glynn Wilson
Director
Period of report
Sep 22, 2018
Accepted (ET)
Sep 25, 2018 · 5:03 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001094038
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common StockF1 | — | Sep 22, 2018 | A | 31,120 | A | — | — | Common Stock | 31,120 | 31,120 | D |
Explanation of responses
- F1Represents the number of shares of restricted stock the reporting person has a present right to receive under the terms of the amendment to his employment agreement with the Company, and such shares are based on a value of $300,000 and the closing price of the Company's common stock on September 21, 2018 of $9.64 per share, (which was the date immediately preceding the anniversary of the amendment) and upon issuance under the Company's 2014 Omnibus Stock Ownership Plan to be fully vested.